Used in combination with daclatasvir, ledipasvir, ribavirin, velpatasvir or with PEG-interferon and ribavirin (see separate entries).
- TRADE NAME: Sovaldi (Gilead)
- INDICATIONS: Hepatitis C
- CLASS: Direct-acting antiviral, Hepatitis C virus nucleotide analog NS5B polymerase inhibitor
- HALF-LIFE: <27 hours
- FDA APPROVAL DATE: 12/06/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, St John's Wort, Tipranavir - PREGNANCY: May cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sofosbuvir in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
